Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

@article{Bakris2015EffectOP,
  title={Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.},
  author={George L Bakris and Bertram C Pitt and Matthew R. Weir and Mason Wright Freeman and Martha R. Mayo and Dahlia Garza and Yuri Stasiv and Rezi Zawadzki and Lance Berman and David A. Bushinsky},
  journal={JAMA},
  year={2015},
  volume={314 2},
  pages={151-61}
}
IMPORTANCE Hyperkalemia is a potentially life-threatening condition predominantly seen in patients treated with renin-angiotensin-aldosterone system (RAAS) inhibitors with stage 3 or greater chronic kidney disease (CKD) who may also have diabetes, heart failure, or both. OBJECTIVES To select starting doses for a phase 3 study and to evaluate the long-term safety and efficacy of a potassium-binding polymer, patiromer, in outpatients with hyperkalemia. DESIGN, SETTING, AND PARTICIPANTS Phase… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

Similar Papers

Loading similar papers…